# Research Loop Progress

## Current Session: h68, h72, h73, h66 (2026-01-31)

### Session Summary

**Agent Role:** Research Executor
**Status:** Completed (4 hypotheses tested)
**Hypotheses Tested:**
- h68: Unified Confidence-Weighted Predictions - **VALIDATED**
- h72: Production Deliverable with Confidence Tiers - **VALIDATED**
- h73: h52 Model Simplification - **VALIDATED**
- h66: Disease Category-Specific k Values - **VALIDATED**

### Key Findings

**h68: Unified Confidence Scoring EXCEEDS TARGET (88% precision)**
- Combined h65, h52, category priors via simple average
- 88.4% precision at threshold 0.7 (exceeds 75% target)
- AP: 0.856, AUC: 0.826

**h72: Production Deliverable Generated**
- 13,416 predictions across 448 diseases
- 2,797 HIGH confidence novel predictions
- Validated: Sirolimus→TSC (FDA-approved), Lovastatin→atherosclerosis
- Output: `data/deliverables/drug_repurposing_predictions_with_confidence.xlsx`

**h73: h52-only Recommended for Production**
- Combined adds +5.9 pp precision but -37% coverage
- h52 at 0.8: 84% precision, 30 diseases (simpler, similar perf)
- Recommendation: Use h52-only for deployment

**h66: Category-Specific k Values Validated**
- 3 categories show >2 pp improvement with optimized k:
  - Metabolic: k=30 (+9.1 pp)
  - Respiratory: k=5 (+8.3 pp)
  - Cancer: k=30 (+3.9 pp)

### New Hypotheses Generated (this session)

| Priority | ID | Title |
|----------|-----|-------|
| 2 | h70 | Threshold Optimization by Use Case |
| 2 | h73 | h52 Model Simplification (completed) |
| 3 | h71 | Per-Category Calibration |

### Updated Pending Hypotheses

| Priority | ID | Title | Effort |
|----------|-----|-------|--------|
| 1 | h69 | Production Pipeline Integration | high |
| 2 | h67 | Drug Class Boosting | medium |
| 2 | h70 | Threshold Optimization | low |
| 3 | h55 | GEO Gene Expression | high |
| 3 | h71 | Per-Category Calibration | medium |
| 4 | h64 | ARCHS4 Real Expression | high |
| 20 | h16 | Clinical Trial Phase Features | medium |

### Session Statistics

- Hypotheses tested: 4
- Validated: 4 (h68, h72, h73, h66)
- Invalidated: 0
- New hypotheses: 4 (h70-h73)
- Deliverables: 1 (Excel + JSON with 13K predictions)
- Models analyzed: 2 (h52, combined ensemble)

### Recommended Next Steps

1. **h69**: Production pipeline integration (deploy h52+category-k)
2. **h70**: Optimize thresholds for different use cases
3. **h67**: Test drug class boosting for additional gains

### Production Deployment Summary

Based on this session's findings, recommended production configuration:

```
Model: models/meta_confidence_model.pkl (h52)
Threshold: 0.8 for HIGH tier, 0.5 for MEDIUM tier
Category-specific k values:
  - k=5: dermatological, cardiovascular, psychiatric, respiratory
  - k=10: autoimmune, gastrointestinal
  - k=20: infectious, neurological (default)
  - k=30: cancer, metabolic, other
Expected precision: ~84% HIGH tier
Expected coverage: ~34% diseases in HIGH tier
```

---

## Previous Sessions

### h61, h57, h65, h62, h63 (2026-01-31)
- 5 hypotheses tested, 2 validated
- Gene-based approaches consistently fail vs Node2Vec
- h65 success predictor achieves 70% precision

### h49-h59 (2026-01-31)
- 9 hypotheses tested, 8 validated
- Major finding: GI diseases are critical blind spot (5% hit rate)
- Extended categories identified clear performance tiers
